Acta clinica Croatica, Vol. 65. No. 2, 2026.
Original scientific paper
https://doi.org/10.20471/acc.2026.65.02.09
Early Efficacy and Hypophosphatemia After Ferric Carboxymaltose Infusion Therapy in Patients With Iron Deficiency Anemia: A Single-Center Experience
Hana Matijaca
orcid.org/0009-0002-7024-0192
; Department of Hematology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
*
Klara Brčić
; Department of Hematology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Klara Grgorinić
orcid.org/0009-0005-8355-3288
; University of Zagreb, School of Medicine, Zagreb, Croatia
Ivan Krečak
orcid.org/0000-0002-8642-305X
; Department of Internal Medicine, General Hospital Šibenik, Šibenik, Croatia; School of Medicine, University of Rijeka, Rijeka, Croatia
Petar Gaćina
; Department of Hematology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia
* Corresponding author.
Abstract
The aim of this study was to investigate the efficacy of ferric carboxymaltose
(FCM) in the correction of iron deficiency anemia and to determine the frequency
and level of hypophosphatemia as a side effect. The data on 28 patients treated
in Sestre milosrdnice University Hospital Center with one or two applications
of FCM in a single dose of 1000 mg, depending on the severity of anemia, was
retrospectively analyzed. The inclusion criteria were hemoglobin < 110 g/L, iron
saturation < 20%, ferritin < 30 μg/L and phosphate > 0.79 mmol/L. Parameters
analyzed before and two weeks after FCM application were complete blood
count (CBC), ferritin, and calcium and phosphate values, while vitamin D and
creatinine levels were determined only once before application. After parenteral
iron supplementation, the expected correction of hemoglobin values and iron
deficiency occurred. The difference in phosphate values before and after FCM
application was statistically significant. The onset of asymptomatic mild to moderate
hypophosphatemia was reported in 67.86% patients. In this study, baseline
hemoglobin and phosphate values were predictive factors of the degree of
hypophosphatemia after FCM administration.
Keywords
Iron deficiency anemia; Sideropenia; Ferric carboxymaltose; Hypophosphatemia
Hrčak ID:
347694
URI
Publication date:
10.6.2026.
Visits: 0 *